NCT03511391 - CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

February 1, 2022

Study Completion Date

January 23, 2024

Conditions

Urothelial CarcinomaMelanomaRenal Cell CarcinomaNon-small Cell Lung CancerHead and Neck Cancer

Interventions

DRUG

Nivolumab or Pembrolizumab or Atezolizumab

per national standard of care

RADIATION

SBRT

Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.

Trial Locations (5)

Jules Bordet Institute, Brussels

GasthuisZusters Antwerpen, Antwerp

AZ Sint-Lucas, Bruges

AZ Sint-Lucas, Ghent

University Hospital Ghent, Ghent